Dabigatran Versus Warfarin With NVAF Who Undergo PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1120 participants.
Also called NCT03536611
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,120 participants
- Registry
-
NCT03536611
-
- Other papers using this trial's data
- Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI)
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03536611. Randomized; single masking; primary purpose treatment. Start 2018-09-01 (actual); primary completion 2019-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dabigatran Versus Warfarin With NVAF Who Undergo PCI
- Acronym
- COACH-AF-PCI
- Condition
- Atrial Fibrillation
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- dabigatran
- Intervention (Drug)
- warfarin
- Lead sponsor
- Shenyang Northern Hospital
- Collaborator
- Beijing Anzhen Hospital
- Collaborator
- Second Affiliated Hospital of Third Military Medical University
Record details
- Record id
cardio:ct-nct03536611- Content hash
e20ed4421e8fbc1ea1761cf827fcd02c0d9575ea938ffdbf123d0c8b393a2147